Why Novo Nordisk's Q3 Miss Is A Buying Opportunity (NVO)
Novo Nordisk A/S ( NVO ) has once again lowered its 2025 outlook . That marks the fourth forecast cut this year as the stock continues to slowly decline. Shares are down 42% year to date. It seemsI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and chall ...